These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32859456)

  • 1. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.
    Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G
    J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
    Yu Y; Huang R; Zong X; He X; Mo W
    BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells.
    Kaji W; Tanaka S; Tsukimoto M; Kojima S
    J Toxicol Sci; 2014 Apr; 39(2):191-8. PubMed ID: 24646699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
    Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
    J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice.
    Zhang Q; Jin L; Jin Q; Wei Q; Sun M; Yue Q; Liu H; Li F; Li H; Ren X; Jin G
    Front Pharmacol; 2021; 12():727275. PubMed ID: 34539408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
    Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
    Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin inhibits activation of the AIM2 inflammasome pathway and NF-κB/HIF-1α/VEGF pathway by inducing autophagy in A431 human cutaneous squamous cell carcinoma cells.
    Wang Y; Li Z; Teng M; Liu J
    Int J Med Sci; 2021; 18(12):2705-2715. PubMed ID: 34104103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neem leaf glycoprotein inhibits CD4+CD25+Foxp3+ Tregs to restrict murine tumor growth.
    Chakraborty T; Bose A; Barik S; Goswami KK; Banerjee S; Goswami S; Ghosh D; Roy S; Chakraborty K; Sarkar K; Baral R
    Immunotherapy; 2011 Aug; 3(8):949-69. PubMed ID: 21843083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway.
    Zhao YG; Wang Y; Guo Z; Gu AD; Dan HC; Baldwin AS; Hao W; Wan YY
    J Immunol; 2012 Nov; 189(9):4417-25. PubMed ID: 22993204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
    Li Y; Sun H; Bai C; Hu Y; Tang J; Zhang Y; Chen J; Zhong Z; He Y; Hu K; Yang J
    Int Immunopharmacol; 2024 May; 133():112157. PubMed ID: 38678671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
    Ramacher M; Umansky V; Efferth T
    Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paeonol inhibits B16F10 melanoma metastasis in vitro and in vivo via disrupting proinflammatory cytokines-mediated NF-κB and STAT3 pathways.
    Zhang L; Tao L; Shi T; Zhang F; Sheng X; Cao Y; Zheng S; Wang A; Qian W; Jiang L; Lu Y
    IUBMB Life; 2015 Oct; 67(10):778-88. PubMed ID: 26452780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TCM formula comprising Sophorae Flos and Lonicerae Japonicae Flos alters compositions of immune cells and molecules of the STAT3 pathway in melanoma microenvironment.
    Liu YX; Bai JX; Li T; Fu XQ; Guo H; Zhu PL; Chan YC; Chou JY; Yin CL; Li JK; Wang YP; Chen YJ; Yu ZL
    Pharmacol Res; 2019 Apr; 142():115-126. PubMed ID: 30797070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-33 pretreatment promotes metastatic growth of murine melanoma by reducing the cytotoxic capacity of CD8
    Jevtovic A; Pantic J; Jovanovic I; Milovanovic M; Stanojevic I; Vojvodic D; Arsenijevic N; Lukic ML; Radosavljevic GD
    Cancer Immunol Immunother; 2020 Aug; 69(8):1461-1475. PubMed ID: 32285171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.